Orphan drugs- developed to treat rare diseases affecting patient populations of fewer than 200,000 people annually - have become a lucrative business opportunity for drug makers. These medications made up almost half of all new drugs approved by the U.S. Food and Drug Administration (FDA) in 2015. 

Read here.